CD8A and neoplasm: APOBEC3H was identified to be a potential prognostic predictor and therapeutic target for oncoimmunotherapy in HNSC, in consideration of its essential role in regulating CXCL10-mediated immune activation and CD8+ T cell infiltration into the tumor microenvironment.